Paris S. Mitrou

Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma

Mathias Rummel, S. Al-Batran, Soo-Z. Kim et al. · Journal of Clinical Oncology · 2005 · 439 citations · Full text

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

Wolfram Pönisch, Paris S. Mitrou, K Merkle et al. · Journal of Cancer Research and Clinical Oncology · 2006 · 190 citations · Full text

Hematological Malignancy, Medicine, Metronomic Therapy +10

Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.

Kai Uwe Chow, Wolf Daniel Sommerlad, Simone Boehrer et al. · PubMed · 2002 · 186 citations

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma

Eckhart Weidmann, S.-Z. Kim, A. Rost et al. · Annals of Oncology · 2002 · 95 citations · Full text

Lymphoid Neoplasia, Medicine, Immunology +6

Interferon-α and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials

Ulrich Keilholz, Carmen Scheibenbogen, Wolfgang Tilgen et al. · Cancer · 1993 · 92 citations